Is NeoGenomics Inc (NEO) overvalued? · $924.0M cap
NeoGenomics Inc (NEO) is a diagnostics & research company listed on US.
This page asks whether NeoGenomics Inc (NEO) looks expensive on cached numbers — not a short thesis.
No cached income statement for NEO, so there is no earnings base to call rich or cheap.
NEO currently screens at market cap $924.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NEO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NEO stock page for the full model, not this heading.
Not investment advice.